Abstract
Neuropathological and biochemical examinations of the brains of patients suffering from senile dementia of the Alzheimer type (SDAT) reveal characterstic abnormalities. These include neurite plaques and neurofibrillary tangles which tend to be localised to the cerebral cortex and hippocampus. In these areas there are also decreased levels of the enzymes and uptake systems present in the nerve terminals which are involved in the synthesis of acetylcholine (for reviews see Bartus et al., 1982; Rossor, 1982; Coyle et al., 1983, 1984; Davies, 1984). In particular, there has been found to be a large reduction in choline-acetyltransferase activity. There is also in SDAT a considerable cell loss in the nucleus basalis of Meynert (Whitehouse et al., 1982; Henke and Lang, 1983). As neurones from this nucleus project to the cerebral cortex and account for an estimated 70% of the cortical content of acetylcholine, it is not surprising that the degeneration of these neurones in SDAT has been assumed to make a contribution to the progression of the disease. It is still not clear whether the primary site of the lesion is in the cell bodies in the basal forebrain or at the cholinergic nerve terminals in the cerebral cortex (Perry et al., 1982; Whitehouse et al., 1982). More importantly, it is not known whether the cholinergic deficit is the primary lesion, as changes in adrenergic, 5-hydroxytryptamine and somatostatin systems have also been observed (for a review, see Rossor and Iversen, 1986).
Preview
Unable to display preview. Download preview PDF.
References
Ashe, J. H., and Yarosh, C. A. (1984). Differential and selective antagonism of the slow-inhibitory postsynaptic potential and slow-excitatory postsynaptic potential by gallamine and pirenzepine in the superior cervical ganglion of the rabbit. Neuropharmacol., 23, 1321–9.
Barlow, R. B., Burston, K. M., and Vis, A. (1980). Three types of muscarinic receptors? Brit. J. Pharmacol, 68, 141P.
Barlow, R. B., Franks, F. M., and Pearson, J. D. M. (1972). A comparison of the affinities of antagonists for acetylcholine receptors in the ileum, bronchial muscle and iris of the guinea-pig. Br. J. Pharmacol, 46, 300–12.
Barlow, R. B., Berry, K. J., Glenton, P. A. N., Nikolau, N. M., and Soh, K. S. (1976). A comparison of affinity constants for muscarine-sensitive acetylcholine receptors in guinea-pig atrial pacemaker cells at 29 °C and in ileum at 29 °C and 37 °C. Br. J. Pharmacol., 58, 613–20.
Barlow, R. B., Caulfield, M. P., Kitchen, R., Roberts, P. M., and Stubley, J. K. (1981). The affinities of pirenzepine and atropine for functional muscarinic receptors in guinea-pig atria and ileum. Br. J. Pharmacol, 73, 183P-4P.
Baron, J. H., and Londong, W. (eds.). (1980). Advances in basic and clinical pharmacology of Pirenzepine. Scand. J. Gastroenterol, 15, Suppl. 66, 1–114.
Bartus, R. T., Dean, R. L., Beer, B., and Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science, 217, 408–17.
Ben-Baruch, G., Schreiber, G., and Sokolovsky, M. (1982). Cooperativity pattern in the interaction of the antiestrogen drug clomiphene with the muscarinic receptors. Mol. Pharmacol., 21, 287–93.
Berrie, C. P., Birdsall, N. J. M., Dadi, H. K., Hulme, E. C., Morris, R. J., Stockton, J. M., and Wheatley, M. (1985). Purification of the muscarinic acetylcholine receptor from rat forebrain. Trans. Biochem. Soc., 13, 1101–3.
Birdsall, N. J. M., and Hulme, E. C. (1983). Muscarinic receptor subclasses. Trends Pharmacol Sci., 4, 459–63.
Birdsall, N. J. M., and Hulme, E. C. (1985). Multiple muscarinic receptors: further problems in receptor classification. Trends Autonom. Pharmacol., 3, 17–34.
Birdsall, N. J. M., Burgen, A. S. V., and Hulme, E. C. (1978). The binding of agonists to brain muscarinic receptors. Molec. Pharmacol, 14, 723–36.
Birdsall, N. J. M., Hulme, E. C., and Stockton, J. M. (1984). Muscarinic receptor heterogeneity. Trends Pharmacol. Sci. Suppl., 4–8.
Birdsall, N. J. M., Burgen, A. S. V., Hulme, E. C., and Stockton, J. M. (1981). Gallamine regulates muscarinic receptors in the heart and cerebral cortex. Br. J. Pharmacol, 74, 798P.
Birdsall, N. J. M., Burgen, A. S. V., Hammer, R., Hulme, E. C., and Stockton, J. M. (1980). Pirenzepine — a ligand with original binding properties to muscarinic receptors. Scand. J. Gastroenterol., 15, Suppl. 66, 1–4.
Birdsall, N. J. M., Burgen, A. S. V., Hulme, E. C., Stockton, J. M., and Zigmond, M. J. (1983a). The effect of McN-A-343 on muscarinic receptors in the cerebral cortex and heart. Br. J. Pharmac., 78, 257–9.
Birdsall, N. J. M., Hulme, E. C., Kromer, W., Stockton, J. M., and Zigmond, M. J. (1986). A second drug binding site on muscarinic receptors. Fed. Proc. (in press).
Birdsall, N. J. M., Hulme, E. C., Stockton, J. M., Burgen, A. S. V., Berrie, C. P., Hammer, R., Wong, E. H. F., and Zigmond, M. J. (1983b). Muscarinic receptor subclasses: evidence from binding studies. In De Feudis, F. V., and Mandel, P. (eds.), CNS Receptors: From Molecular Pharmacology to Behaviour, Raven Press, New York, pp. 323–9.
Black, J. W., Leff, P., and Shankley, N. P. (1985). Further analysis of anomalous pKB values for muscarinic antagonists on the mouse stomach assay. Br. J. Pharmacol., 85, 212P.
Blum, A. L., and Hammer, R. (eds.) (1979). Die Behandlung des Ulcus pepticum mit Pirenzepin. Demeter Verlag, Munich.
Bowen, D. M., Spillane, J. A., Curzon, G., Meier-Ruge, W., White, P., Goodhardt, M. J., Iwangoff, P., and Davison, A. N. (1979). Accelerated aging on selective neuron loss as an important cause of dementia. Lancet, i, 11–14.
Breitwieser, G. E., and Szabo, G. (1985). Uncoupling of cardiac muscarinic and adrenergic receptors from ion channels by a guanine nucleotide analogue. Nature, 317, 538–40.
Brown, D. A., Forward, A., and Marsh, S. (1980). Antagonist discrimination between ganglionic and ileal muscarinic receptors. Br. J. Pharmac., 71, 362–4.
Caulfield, M., and Straughan, D. (1983). Muscarinic receptors revisited. Trends Neurosci., 6, 73–5.
Caulfield, M. P., and Stubley, J. K. (1982). Pilocarpine selectively stimulates muscarinic receptors in rat sympathetic ganglia. Br. J. Pharmacol, 76, 216P.
Caulfield, M. P., Straughan, D. W., Cross, A. J., Crow, T. J., and Birdsall, N. J. M. (1982). Cortical muscarinic receptor subtypes and Alzheimer’s disease. Lancet, ii, 1279–80.
Changeux, J. P. (1966). Responses of acetylcholinesterase from Torpedo marmorata to salts and curarising agents. Mol Pharmacol., 2, 369–92.
Chassaing, C., Dureng, G., Baissat, J., and Duchene-Marullaz, P. (1984). Pharmacological evidence for cardiac muscarinic receptor subtypes. Life Sci., 35, 1739–45.
Clague, R. U., Eglen, R. M., Strachan, A. C., and Whiting, R. L. (1985). Action of agonists and antagonists at muscarinic receptors present on ileum and atria in vitro. Brit. J. Pharmacol, 86, 163–70.
Clark, A. L., and Mitchelson, F. (1976). The inhibitory effect of gallamine on muscarinic receptors. Br. J. Pharmac., 58, 323–31.
Cohen-Armon, M., Henis, Y. I., Kloog, Y., and Sokolovsky, M. (1985). Interactions of quinidine and lidocaine with rat brain and heart muscarinic receptors. Biochem. Biophys. Res. Commun., 127, 326–32.
Coyle, J. T., Price, D. L., and DeLong, M. R. (1983). Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science, 219, 1184–90.
Coyle, J. T., Price, D. L., and DeLong, M. R. (1984). Anatomy of cholinergic projections to cerebral cortex: implications for the pathophysiology of senile dementia of the Alzheimer’s type. Trends Pharmacol. Sci. Suppl., 90–3.
Daly, M. J., Humphrey, J. M., and Stables, R. (1982). Effects of H2-receptor antagonists and anticholinoceptor drugs on gastric and salivary secretion induced by bethanechol in the anaesthetised dog. Br. J. Pharmacol., 76, 361–5.
Davies, P. (1984). Neurochemical aspects of Alzheimer’s disease. Trends Pharmacol. Sci. Suppl., 98–9.
Davies, P., and Verth, A. H. (1978). Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer’s type dementia brains. Brain Res., 138, 385–92.
Deutsch, J. A. (1971). The cholinergic synapse and the site of memory. Science, 174. 788–93.
Doteval, G., Jaup, B. H., and Stockbrugger, R. W. (eds.) (1982). On the selectivity of anti-muscarinic compounds. Scand. J. Gastroenterol, 17, Suppl. 72, 1–273.
Drachman, D. A. (1977). Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology, 27, 783–90.
Drachman, D., and Leavitt, J. (1974). Human memory and the cholinergic system: a relationship to aging? Arch. Neurol., 30, 113–20.
Dunlap, J., and Brown, J. H. (1983). Heterogeneity of binding sites on cardiac muscarinic receptors induced by the neuromuscular blocking agents gallamine and pancuronium. Molec. Pharmacol, 24, 15–22.
Egan, T. M., and North, R. A. (1985). Acetylcholine acts on m2-muscarinic receptors to excite rat locus coeruleus neurones. Br. J. Pharmacol, 85, 733–5.
Ellis, J., and Lenox, R. H. (1985). Characterisation of the interactions of gallamine with muscaric receptors from brain. Biochem. Pharmacol., 34, 2214–17.
Eltze, M., Gonne, S., Riedel, R., Schlotke, B., Schudt, C., and Simon, W. A. (1985). Pharmacological evidence for selective inhibition of gastric acid secretion by telenzepine, a new antimuscarinic drug. Eur. J. Pharmacol., 112, 211–24.
Fisher, S. K. (1986). Inositol lipids and signal transduction at CNS muscarinic receptors. Trends Pharmacol Sci. Suppl. 61–5.
Fisher, S. K., and Bartus, R. T. (1985). Regional differences in the coupling of muscarinic receptors to inositol phospholipid hydrolysis in guinea-pig brain. J. Neurochem., 45, 1085–95.
Fisher, A., Weinstock, M., Glitter, S., and Cohen, S. (1976). A new probe for heterogeneity in muscarinic receptors: 2-methyl-spiro(1,3-dioxolane-4,3ʹ)-quinuclidine. Eur. J. Pharmacol, 37, 329–38.
Franko, B. V., Ward, J. W., and Alphin, R. S. (1963). Pharmacologic studies of N-benzyl-3-pyrrolidinyl acetate methobromide (AHR-602), a ganglion stimulating agent. J. Pharmacol. exp. Ther., 139, 25–30.
Fuder, H., Rink, D., and Muscholl, E. (1982). Sympathetic nerve stimulation on the perfused rat heart. Affinities of N-methylatropine and pirenzepine at pre- and postsynaptic muscarine receptors. Naunyn Schmiedeberg’s Arch Pharmacol., 318, 210–19.
Fuder, H., Meiser, C., Wormstall, H., and Muscholl, E. (1981). The effects of several muscarinic antagonists on pre- and postsynaptic receptors in the isolated heart. Naunyn Schmiedeberg’s Arch. Pharmacol., 316, 31–7.
Giachetti, A., Micheletti, R., and Montagna, E. (1986). Cardio selective profile of AF-DX 116, a muscarine M2 receptor antagonist. Fed. Proc. (in press).
Gil, D. W., and Wolfe, B. B. (1985). Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase. J. Pharm. exptl Ther., 232, 608–16.
Growdon, J. H., Corkin, S., and Huff, F. J. (1985). Clinical evaluation of compounds for the treatment of memory dysfunction. Ann. N. Y. Acad. Sci., 444, 437–49.
Hammer, R. (1982). Subclasses of muscarinic receptors and pirenzepine. Further experimental evidence. Scand. J. Gastroenterol., 17, Suppl. 72, 59–67.
Hammer, R., and Giachetti, A. (1982). Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. Life Sci., 31, 2991–8.
Hammer, R., and Giachetti, A. (1984). Selective muscarinic receptor antagonists. Trends Pharmacol. Sci., 5, 18–20.
Hammer, R., Berrie, C. P., Birdsall, N. J. M., Burgen, A. S. V., and Hulme, E. C. (1980). Pirenzepine distinguishes between subclasses of muscarinic receptor. Nature (Lond.), 283, 90–2.
Hammer, R., Giraldo, E., Schiavi, G. B., Monferini, E., and Ladinsky, H. (1986). Binding profile of a novel cardio selective muscarine receptor antagonist. AF-DX 116 to membranes of peripheral tissues and brain in the rat. Life Sci., 38, 1653–62.
Harbaugh, R. E., Roberts, D. W., Coombs, D. W., Sauders, R. L., and Reeder, T. M. Intracranial cholinergic drug infusion in patients with Alzheimer’s disease. Neurosurgery, 15, 514–18.
Henke, H., and Lang, W. (1983). Cholinergic enzymes in neocortex, hippocampus and basal forebrain of non-neurologicaland senile dementia of Alzheimer-type patients. Brain Res., 267, 281–91.
Hirschowitz, B. I., Hammer, R., Giachetti, A., Kierns, J. J., and Levine, R. R. (eds.). (1984). Subtypes of muscarinic receptors. Trends Pharmacol. Sci. Suppl., 1–103.
Hulme, E. C., Berrie, C. P., Birdsall, N. J. M., and Burgen, A. S. V. (1981). Interactions of muscarinic receptors with guanine nucleotides and adenylate cyclase. In Birdsall, N. J. M. (ed.), Drug Receptors and their Effectors. Macmillan, London, 23–4.
Hulme, E. C., Berrie, C. P., Birdsall, N. J. M., Jameson, M., and Stockton, J. M. (1983). Regulation of muscarinic agonist binding by cations and guanine nucleotides. Eur. J. Pharmacol., 94, 59–72.
Jacobson, M. D., Wusternan, M., and Downes, C. P. (1985). Muscarinic receptors and hydrolysis of inositol phospholipids in rat cerebral cortex and parotid gland. J. Neurochem., 44, 465–72.
Jagadeesh, G., and Sulakhe, P. V. (1985). Gallamine binding to heart M2 cholinergic receptors does not antagonize cholinergic inhibition of adenylate cyclase in isolated plasma membrane. Eur. J. Pharmacol., 109, 311–13.
Jaup, B. H., Stockbrugger, R. W., and Doteval, G. (1982). Comparison between the effects of pirenzepine and 1-hyoscyamine in man. Scand. J. Gastroenterol., 17, Suppl. 72, 119–22.
Kharkevich, D. A. and Shorr, V. A. (1980). Cardiotropic antimuscarinic action of some curare-like agents. Arch. Int. Pharmacodyn. Ther., 248, 238–50.
Kilbinger, H. (1984a). Presynaptic muscarine receptors modulating acetylcholine release. Trends Pharmacol. Sci., 5, 103–5.
Kilbinger, H. (1984b). Facilitation and inhibition by muscarinic agonists of acetylcholine release from guinea-pig myenteric neurones: mediation through different types of neuronal muscarinic receptors. Trends Pharmacol. Sci. Suppl., 49–52.
Kilbinger, H., and Nafziger, M. (1985). Two types of neuronal muscarinic receptors modulating acetylcholine release from guinea-pig myenteric plexus. Naunyn-Schmiedeberg’s Arch. Pharmacol, 328, 304–9.
Kurose, H., Katada, T., Amano, T., and Ui, M. (1983). Specific uncoupling by islet-activating protein, pertussis toxin, of negative signal transduction via α2-adrenergic, cholinergic and opiate receptors in neuroblastoma × glioma hybrid cells. J. Biol Chem., 258, 4870–5.
Lai, W. S., Ramkumar, V., and El-Fakahany, E. E. (1985). Possible allosteric interaction of 4-aminopyridine with rat brain muscarinic acetylcholine receptors, J. Neurochem., 44, 1936–42.
Lang, W., and Henke, H. (1983). Cholinergic receptor binding and autoradiography in brains of non-neurological and senile dementia of Alzheimer-type patients. Brain Res., 267, 271–80.
Lazareno, S., Kendall, D. A., and Nahorski, S. R. (1985). Pirenzepine indicates heterogeneity of muscarinic receptors linked to cerebral inositol phospholipid metabolism. Neuropharmacol., 24, 593–5.
Li, C. K., and Mitchelson, F. (1980). The selective antimuscarinic action of stercuronium. Br. J. Pharmacol., 70, 313–21.
Leung, E., and Mitchelson, F. (1982). The interaction of pancuronium with cardiac and ileal muscarinic receptors. Eur. J. Pharmacol., 80, 1–9.
Levy, R. (1985). Rational drug treatment of dementia? Br. Med. J., 291, 139.
Luthin, G. R., and Wolfe, B. B. (1984a). Comparison of [3H]-pirenzepine and [3H]-quin-uclidinyl benzilate binding to muscarinic cholinergic receptors in rat brain. J. Pharmacol Expl. Ther., 228, 648–55.
Luthin, G. R., and Wolfe, B. B. (1984b). [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization. Molec. Pharmacol., 26, 164–9.
Marshall, R. J., McGrath, J. C., Miller, R. D., Docherty, J. R., and Lamar, J.-C. (1980). Comparison of the cardiovascular actions of ORG NC 45 with those produced by other non-depolarising neuromuscular blocking agents in experimental animals. Br. J. Anaesth., 52, 215–325.
Mash, D. C., Flynn, D. D., and Potter, L. T. (1985). Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation. Science, 288, 115–17.
Mitchelson, F. (1984). Heterogeneity of muscarinic receptors: evidence from pharmacologic studies with antagonists. Trends Pharmacol. Sci. Suppl., 12–16.
Murad, F., Chi, Y.-M., Rall, T. W., and Sutherland, E. W. (1962). Adenyl cyclase III. The effect of catecholamines and choline esters on the formation of adenosine 3′,5′-phosphate by preparations from cardiac muscle and liver. J. Biol. Chem., 237, 1233–8.
Mutschler, E., and Lambrecht, G. (1984). Selective muscarinic agonists and antagonists in functional tests. Trends Pharmacol Sci. Suppl, 39–44.
Nedoma, J., Dorofeeva, N. A., Tucek, S., Shelkovnikov, S. A., and Danilov, A. F. (1985). Interaction of the neuromuscular blocking drugs alcuronium, decamethonium, gallamine, pancuronium, ritebronium, tercuronium and d-tubocurarine with muscarinic acetylcholine receptors in the heart and ileum. Naunyn Schmiedeberg’s Arch. Pharmacol., 329, 176–81.
Nordstrom, O., Alberts, P., Westlind, A., Unden, A., and Bartfai, T. (1983). Presynaptic antagonist-postsynaptic agonist at muscarinic cholinergic synapses. Mol. Pharmacol., 24, 1–5.
North, R. A. (1986). Muscarinic receptors and membrane ion conductances. Trends Pharmacol. Sci. Suppl, 19–22.
Pagani, F., Schiavone, E., Monferini, E., Hammer, R., and Giachetti, A. (1984). Distinct muscarinic receptor subtypes (M1 and M2) controlling acid secretion in rodents. Trends Pharmacol Sci. Suppl., 66–8.
Parsons, M. E., Bunce, T., Blakemore, C., and Rasmussen, C. (1979). Pharmacological studies on the gastric antisecretory agent, pirenzepine. In Blum, A. L., and Hammer, R. (eds.), Die Behandlung des Ulcus pepticum mit Pirenzepin. Demeter Verlag, Munich, pp. 26–34.
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., and Perry, R. H. (1978). Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Brit. Med. J., 25, 1457–9.
Perry, R. H., Candy, J. M., Perry, E. K., Irving, D., Blessed, G., Fairbairn, A. F., and Tomlinson, B. E. (1982). Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer’s disease. Neurosci. Lett., 33, 311–15.
Pfaffinger, P. J., Martin, J. M., Hunter, D. D., Nathanson, N. M., and Hille, B. (1985). GTP-binding proteins couple cardiac muscarinic receptors to a K channel. Nature, 317, 536–8.
Porsius, A. J., Wilffert, B., Lambrecht, G., Moser, U., and Mutschler, E. (1981). Muscarinic effects of various isoarecaidine esters in sympathetic ganglia. J. Auton. Pharmacol, 1, 119–26.
Potter, L. T., Flynn, D. D., Hanchett, H. E., Kalinoski, D. L., Luber-Narod, J., and Mash, D. C. (1984). Independent M1 and M2 receptors: ligands, autoradiography and functions. Trends Pharmacol. Sci. Suppl, 22–31.
Raiteri, M., Leardi, R., and Marchi, M. (1984). Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. J. Pharm. expl Therap., 228, 209–14.
Reisine, T. D., Yamamura, H. I., Bird, E. D., Spokes, E., and Enna, S. J. (1978). Pre- and post-synaptic neurochemical alterations in Alzheimer’s disease. Brain Res., 159, 477–80.
Riker, W. F., and Wescoe, W. C. (1951). The pharmacology of flaxedil with observations on certain analogs. Ann. N. Y. Acad. Sci., 54, 373–94.
Rinne, J. O., Rinne, J. K., Laakso, K., Paljarvi, L., and Rinne, U. K. (1984). Reduction in muscarinic receptor binding in limbic areas of Alzheimer brain. J. Neurol Neurosurg. Psychiat., 47, 651–3.
Rosenfeld, E. C. (1983). Pirenzepine (LS 519): A weak inhibitor of acid secretion in isolated rat parietal cells. Eur. J. Pharmacol., 86, 99–101.
Rossor, M. N. (1982). Dementia. Lancet, ii, 1200–4.
Rossor, M. N., and Iversen, L. L. (1986). Non-cholinergic neurotransmission abnormalities in Alzheimer’s disease. Br. Med. Bull., 42, 1–114.
Roszkowski, A. P. (1961) An unusual type of sympathetic ganglionic stimulant. J. Pharmacol. Exp. Ther., 132, 156–70.
Sitaram, N., Weingartner, H., and Gillin, J. C. (1978). Human serial learning: enhancement with arecholine and choline and impairment with scopolamine. Science, 201, 274–6.
Smith, T. L., and Yamamura, H. I. (1985). Carbachol stimulation of phosphatidic acid synthesis: competitive inhibition by pirenzepine in synaptosomes from rat cerebral cortex. Biochem. Biophys. Res. Commun., 130, 282–5.
Soejima, M., and Noma, A. (1984). Mode of regulation of the ACh-sensitive K-channel by the muscarinic receptor in rabbit atrial cells. Pflugers Arch., 400, 424.
Sokolovsky, M. (1984). Muscarinic receptors in the central nervous system. Int. Rev. Neurobiol., 25, 139–83.
Soll, A. H. (1984). Fundic mucosal muscarinic receptors modulating acid secretion. Trends Pharmacol. Sci. Suppl, 60–2.
Stockton, J., Birdsall, N. J. M., Burgen, A. S. V., and Hulme, E. C. (1983). Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol., 23, 551–7.
Szelenyi, I. (1982). Does pirenzepine distinguish between ‘subtypes’ of muscarinic receptors. Br. J. Pharmacol., 77, 567–9.
Tien, X.-Y., and Wallace, L. J. (1985). Trihexyphenidyl — further evidence for muscarinic receptor subclassification. Biochem. Pharmacol, 34, 588–90.
Waelbroeck, M., Robberecht, P., De Neff, P., and Christophe, J. (1984). Effects of verapamil on the binding properties of rat heart muscarinic receptors: evidence for an allosteric site. Biochem. Biophys. Res. Commun., 121, 340–5.
Watson, M., Roeske, W. R., and Yamamura, H. I. (1982). [3H] pirenzepine selectively identifies a high affinity population of muscarinic cholinergic receptors in the rat cerebral cortex. Life Sci., 31, 2019–23.
Watson, M., Yamamura, H. I., and Roeske, W. R. (1983). A unique regulatory profile and regional distribution of [3H] pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes. Life Sci., 32, 3001–11.
Watson, M., Vickroy, T. W., Roeske, W. R., and Yamamura, H. I. (1984). Subclassification of muscarinic receptors based upon the selective antagonist pirenzepine. Trends Pharmacol. Sci. Suppl., 9–11.
Wettstein, A., and Spiegel, R. (1984). Clinical trials with the cholinergic drug RS 86 in Alzheimer’s disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacol., 84, 572–3.
White, P., Hiley, C. R., Goodhart, M. J., Carrasco, L. H., Keet, J. P., Williams, I. E. I., and Bowen, D. M. (1977). Neocortical cholinergic neurons in elderly people. Lancet, i, 668–71.
Whitehouse, P. J., Price, D. L., Struble, R. G., Clark, A. W., Coyle, J. T., and De Long, M. R. (1982). Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science, 215, 1237–9.
Wood, P. L., Etienne, P., Lai, S., Nair, N. P., Finlayson, M. H., Gauthier, S., Palo, J., Haltia, M., Paetau, A., and Bird, E. D. (1983). A post-mortem comparison of the cortical cholinergic system in Alzheimer’s disease and Pick’s disease. J. neurol. Sci., 62, 211–17.
Yamamura, H. I., Wamsley, J. K., Deshmukh, P., and Roeske, W. R. (1983). Differential light microscopic autoradiographic localisation of muscarinic cholinergic receptors in the brainstem and spinal cord of the rat using [3H] pirenzepine. Eur. J. Pharmacol., 91, 147–9.
Editor information
Editors and Affiliations
Copyright information
© 1986 The Editors and the Contributors
About this chapter
Cite this chapter
Birdsall, N.J.M., Hulme, E.C., Kromer, W., Peck, B.S., Stockton, J.M., Zigmond, M.J. (1986). Two Drug Binding Sites on Muscarinic Receptors. In: Briley, M., Kato, A., Weber, M. (eds) New Concepts in Alzheimer’s Disease. Palgrave, London. https://doi.org/10.1007/978-1-349-08639-9_9
Download citation
DOI: https://doi.org/10.1007/978-1-349-08639-9_9
Publisher Name: Palgrave, London
Print ISBN: 978-1-349-08641-2
Online ISBN: 978-1-349-08639-9
eBook Packages: MedicineMedicine (R0)